Patents by Inventor Semra Yoruk

Semra Yoruk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic RNA and Anti-PD1 Antibodies for Advanced Stage Solid Tumor Cancers
    Publication number: 20220288199
    Abstract: This disclosure relates to the field of therapeutic RNAs for treatment of subjects that have failed, or become intolerant, resistant, or refractory to an anti-programmed cell death 1 (PD-1) or anti-programmed cell death 1 ligand 1 (PD-L1) therapy, including innate and acquired PD-1 and/or PD-L1 therapy, as well as in subjects with advanced-stage, unresectable, or metastatic solid tumor cancers with or without failure, intolerance, resistance, or refraction to an anti-programmed cell death 1 (PD-1) or anti-programmed cell death 1 ligand 1 (PD-L1) therapy.
    Type: Application
    Filed: July 20, 2021
    Publication date: September 15, 2022
    Applicant: SANOFI
    Inventors: Serena MASCIARI, Semra YORUK, Karl HSU, Timothy R. WAGENAAR, Nicolas ACQUAVELLA, Marie BERNARDO, Robert JABULOWSKY, Ugur SAHIN, Friederike GIESEKE, Zuzana JIRAKOVA TRNKOVA
  • USE OF ANTI-CEACAM5 IMMUNOCONJUGATES FOR TREATING LUNG CANCER
    Publication number: 20220080053
    Abstract: The present disclosure provides methods of treating high CEACAM5 expressing cancers including lung cancers such NSQ NSCLC using immunoconjugates comprising an antibody that specifically binds human CEACAM5.
    Type: Application
    Filed: February 6, 2020
    Publication date: March 17, 2022
    Inventors: Aurore ALLARD, Mustapha CHADJAA, Cécile COMBEAU, Brigitte DEMERS, Christophe HENRY, Semra YORUK
  • Therapeutic RNA for Advanced Stage Solid Tumor Cancers
    Publication number: 20220040218
    Abstract: This disclosure relates to the field of therapeutic RNAs for treatment of subjects that have failed, or become intolerant, resistant, or refractory to an anti-programmed cell death 1 (PD-1) or anti-programmed cell death 1 ligand 1 (PD-L1) therapy, including innate and acquired PD-1 and/or PD-L1 therapy, as well as in subjects with advanced-stage, unresectable, or metastatic solid tumor cancers with or without failure, intolerance, resistance, or refraction to an anti-programmed cell death 1 (PD-1) or anti-programmed cell death 1 ligand 1 (PD-L1) therapy.
    Type: Application
    Filed: July 20, 2021
    Publication date: February 10, 2022
    Applicant: SANOFI
    Inventors: Serena Masciari, Semra Yoruk, Karl Hsu, Timothy R. Wagenaar, Nicolas Acquavella, Marie Bernardo, Robert Jabulowsky, Ugur Sahin, Friederike Gieseke, Zuzana Jirakova Trnkova